{Reference Type}: Journal Article
{Title}: Emerging mRNA Technology for Liver Disease Therapy.
{Author}: Wang J;Fang Y;Luo Z;Wang J;Zhao Y;
{Journal}: ACS Nano
{Volume}: 0
{Issue}: 0
{Year}: 2024 Jun 25
{Factor}: 18.027
{DOI}: 10.1021/acsnano.4c02987
{Abstract}: Liver diseases have consistently posed substantial challenges to global health. It is crucial to find innovative methods to effectively prevent and treat these diseases. In recent times, there has been an increasing interest in the use of mRNA formulations that accumulate in liver tissue for the treatment of hepatic diseases. In this review, we start by providing a detailed introduction to the mRNA technology. Afterward, we highlight types of liver diseases, discussing their causes, risks, and common therapeutic strategies. Additionally, we summarize the latest advancements in mRNA technology for the treatment of liver diseases. This includes systems based on hepatocyte growth factor, hepatitis B virus antibody, left-right determination factor 1, human hepatocyte nuclear factor α, interleukin-12, methylmalonyl-coenzyme A mutase, etc. Lastly, we provide an outlook on the potential of mRNA technology for the treatment of liver diseases, while also highlighting the various technical challenges that need to be addressed. Despite these difficulties, mRNA-based therapeutic strategies may change traditional treatment methods, bringing hope to patients with liver diseases.